Yeda Research and Develpment & Co. Ltd

Immunobrain Checkpoint, Inc.

Carol David

Michal Eisenbach-Schwartz

Kuti Baruch

Jan Egebjerg

Ester Yoles

Berit Olsen Krogh

Allan Jensen

The present specification discloses modified anti-PD-L1 antibodies that abolishes Fc-related effector function and enhances clearance rate while maintaining therapeutic efficacy for neurodegenerative disease modification. The present specification also discloses nucleic acid sequences and expression constructs encoding such modified anti-PD-L1 antibodies as well as methods of making such modified anti-PD-L1 antibodies. In addition, the present specification discloses methods of treatment and uses that employ an administration regime of the disclosed anti-PD-L1 antibodies that ensures the antibodies are present for only a specific period of time and then are sufficiently cleared from the body to ensure treatment efficacy is maintained.

Modified anti-PD-L1 antibody and methods and uses for treating a neurodegenerative disease

Growing community of inventors

Rehovot, Israel

Carol David